Crocin treatment improves testosterone induced benign prostatic hyperplasia in rats

Background and objective: Benign prostatic hyperplasia (BPH) is a typical nonmalignant growth of the prostate in the elderly. Crocin, a bioactive component of Crocus sativus L., commonly known as saffron, is known to have an anti-proliferative activity against numerous types of cancer, including prostate cancer. This study investigated the effects of crocin on testosterone-induced BPH development in rats.

Materials and methods: The study sample included three groups of adult male rats (3 months old, weighed 250 g): the control group received corn oil only, the second and the third groups were injected with testosterone (3 mg/kg dissolved in corn oil) subcutaneously. The second group was considered as testosterone-induced BPH (untreated) while the third groups were assigned as testosterone-induced BPH-crocin treated group (100 mg/kg orally for 14 days).

Results: After animal sacrifice, histopathological analysis of the prostate tissues was performed in parallel with gene expression of proliferation (PCNA), inflammation (IL-6), and vascularization (VEGF-A) markers, analyzed by qRT-PCR. Crocin treatment significantly reduced prostate index and the thickness of the epithelial layer in rats with BPH. Additionally, the mRNA expression levels of PCNA, a marker of cell proliferation; IL-6, an inflammatory cytokine; and VEGF-A, an angiogenesis marker, were significantly down-regulated in the BPH group that were treated with crocin.

Conclusions: The present study indicates that crocin can effectively prevent the development of experimentally induced BPH through inhibition of prostatic cellular proliferation, inflammation, and angiogenesis.

Crocin; BPH; RT-PCR; Testosterone; Rats

[1] Roehrborn CG. Benign prostatic hyperplasia: an overview. Reviews in urology. 2005; 7: S3–S14.

[2] Shah A, Shah AA, K N, Lobo R. Mechanistic targets for BPH and prostate cancer—a review. Reviews on Environmental Health. 2020.(in press)

[3] Al-Trad B, Aljabali A, Al Zoubi M, Shehab M, Omari S. Effect of gold nanoparticles treatment on the testosterone-induced benign prostatic hyperplasia in rats. International Journal of Nanomedicine. 2019; 14: 3145–3154.

[4] Li J, Tian Y, Guo S, Gu H, Yuan Q, Xie X. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PLoS ONE. 2018; 13: e0191469.

[5] Toivanen R, Shen MM. Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development. 2017; 144: 1382–1398.

[6] Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: a Mini-Review. Gerontology. 2019; 65: 458–464.

[7] Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Current Urology Reports. 2008; 9: 272–278.

[8] Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Medical Clinics of North America. 2011; 95: 87–100.

[9] Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate. 1995; 26: 111–115.

[10] Walsh K, Sriprasad S, Hopster D, Codd J, Mulvin D. Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Prostate Cancer and Prostatic Diseases. 2002; 5: 119–122.

[11] Krušlin B, Tomas D, Džombeta T, Milković-Periša M, Ulamec M. Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach. Frontiers in Oncology. 2017; 7: 77.

[12] Zhu K, Yang C, Dai H, Li J, Liu W, Luo Y, et al. Crocin inhibits titanium particle-induced inflammation and promotes osteogenesis by regu-lating macrophage polarization. International Immunopharmacology. 2019; 76: 105865.

[13] Yaribeygi H, Mohammadi MT, Sahebkar A. Crocin potentiates antioxidant defense system and improves oxidative damage in liver tissue in diabetic rats. Biomedicine & Pharmacotherapy. 2018; 98: 333–337.

[14] Mohammadzadeh L, Hosseinzadeh H, Abnous K, Razavi BM. Neuro-protective potential of crocin against malathion-induced motor deficit and neurochemical alterations in rats. Environmental Science and Pollution Research International. 2018; 25: 4904–4914.

[15] Jiang Z, Gu M, Liu J, Li H, Peng J, Zhang Y. Anticancer activity of crocin against cervical carcinoma (HeLa cells): Bioassessment and toxicity evaluation of crocin in male albino rats. Journal of Photochemistry and Photobiology B: Biology. 2018; 180: 118–124.

[16] Lambrianidou A, Koutsougianni F, Papapostolou I, Dimas K.Recent Advances on the Anticancer Properties of Saffron (Crocus sativus L.) and Its Major Constituents. Molecules.2021; 26: 86.

[17] Bakshi HA, Hakkim FL, Sam S, Javid F, Rashan L. Dietary crocin reverses melanoma metastasis. Journal of Biomedical Research. 2018; 32: 39–50.

[18] El-Ashmawy NE, Khedr EG, El-Bahrawy HA, Helmy NN. Modulatory Effect of Silymarin on Apoptosis in Testosterone -Induced Benign Prostatic Hyperplasia in Rats. Pathology & Oncology Research. 2020; 26: 1947–1956.

[19] Al-Trad B, Al-Zoubi M, Qar J, Al-Batayneh K, Hussien E, Muhaidat R, et al. Inhibitory Effect of Thymoquinone on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats. Phytotherapy Research. 2017; 31: 1910–1915.

[20] Bakshi HA, Zoubi MSA, Hakkim FL, Aljabali AAA, Rabi FA, Hafiz AA, et al. Dietary crocin is protective in pancreatic cancer while reducing radiation-induced hepatic oxidative damage. Nutrients. 2020; 12: 1901.

[21] Al-Trad B, Al Zoubi M, Migdady M, Lahham J, A Aljabali A, Shehab M, et al. Effects of Artemisia judaica essential oil and ethanolic extract on experimentally-induced benign prostatic hyperplasia. Pharmacog-nosy Magazine. 2020; 16: 569.

[22] Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M, et al. Benign Prostatic Hyperplasia and its Aetiologies. European Urology Supplements. 2009; 8: 865–871.

[23] Juríková M, Danihel Ľ, Polák Š, Varga I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochemica. 2016; 118: 544–552.

[24] Zhong W, Peng J, He H, Wu D, Han Z, Bi X, et al. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clinical and Investigative Medicine. 2008; 31: E8–E15.

[25] D’Alessandro AM, Mancini A, Lizzi AR, De Simone A, Marroccella CE, Gravina GL, et al. Crocus sativus stigma extract and its major constituent crocin possess significant antiproliferative properties against human prostate cancer. Nutrition and Cancer. 2013; 65: 930–942.

[26] Fernández J. Anticancer properties of saffron, Crocus sativus Linn. Advances in phytomedicine. 2006; 2: 313–330.

[27] Hire RR, Srivastava S, Davis MB, Kumar Konreddy A, Panda D. An-tiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer Cells. Scientific Reports. 2017; 7: 44984.

[28] La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016; 4: 404–411.

[29] Korani S, Korani M, Sathyapalan T, Sahebkar A. Therapeutic effects of Crocin in autoimmune diseases: a review. BioFactors. 2019; 45: 835–843.

[30] Liu W, Sun Y, Cheng Z, Guo Y, Liu P, Wen Y. Crocin exerts anti-inflammatory and anti-arthritic effects on type II collagen-induced arthritis in rats. Pharmaceutical Biology. 2018; 56: 209–216.

[31] Chen S, Gu Y, Lu F, Qian D, Dong T, Ding Z, et al. Antiangiogenic effect of crocin on breast cancer cell MDA-MB-231. Journal of Thoracic Disease. 2019; 11: 4464–4473.

[32] Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, Agnantis NJ. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.In Vivo. 2004; 18: 155–160.